Home/Filings/4/0001209191-12-031019
4//SEC Filing

VERTEX PHARMACEUTICALS INC / MA 4

Accession 0001209191-12-031019

$VRTXCIK 0000875320operating

Filed

May 28, 8:00 PM ET

Accepted

May 29, 4:26 PM ET

Size

7.5 KB

Accession

0001209191-12-031019

Insider Transaction Report

Form 4
Period: 2012-05-24
Kelly Lisa
SVP, Human Resources
Transactions
  • Sale

    Common Stock

    2012-05-24$62.74/sh900$56,46622,355 total
  • Sale

    Common Stock

    2012-05-24$63.38/sh5,106$323,61817,249 total
Holdings
  • Common Stock

    (indirect: By 401(k))
    1,667
Footnotes (4)
  • [F1]Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1.
  • [F2]Open market sales reported on this line occurred at a weighted average price of $62.74 (range $62.25 to $62.99).
  • [F3]Ms. Kelly-Croswell undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
  • [F4]Open market sales reported on this line occurred at a weighted average price of $63.38 (range $63.06 to $63.62).

Issuer

VERTEX PHARMACEUTICALS INC / MA

CIK 0000875320

Entity typeoperating
IncorporatedMA

Related Parties

1
  • filerCIK 0000875320

Filing Metadata

Form type
4
Filed
May 28, 8:00 PM ET
Accepted
May 29, 4:26 PM ET
Size
7.5 KB